Clinical Trials Logo

Erythema clinical trials

View clinical trials related to Erythema.

Filter by:

NCT ID: NCT05792306 Completed - Skin Injury Clinical Trials

The Novel Electrolyzed Water Spray Treatment Discomfort, Redness and Swelling of the Skin Surrounding the Wound

Start date: January 29, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to test whether the reduction of the sense of discomfort and redness and swelling of the skin surrounding the wound of patients by use of the novel electrolyzed water spray will relieve the inflammation of the skin.

NCT ID: NCT05765513 Completed - Periodontitis Clinical Trials

HA35 Treatment the Gingival Discomfort as Well as Gingival Redness and Bleeding of Patients With Periodontitis

Start date: February 2, 2023
Phase: N/A
Study type: Interventional

The main objective of this study is to research the treatment of 35 kDa hyaluronan fragment HA35 for Mild periodontitis and associated with gingival discomfort or itchiness.

NCT ID: NCT05742347 Enrolling by invitation - Erythema Clinical Trials

Skin Protectant Textile Efficacy Study for Managing Skin Fold Conditions

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This study will evaluate the efficacy of the DriGo skin protectant textile (SPT) to manage erythema, maceration, denudation, satellite lesions, pain, itching, burning, moisture, and odor associated with skin folds (henceforth together referred to as "skin fold conditions"). Participants will be patients with skin fold conditions, which will be treated with the SPT. Healthcare providers will apply the SPT to the participants' target areas. An independent licensed clinician with experience in identifying and treating skin fold conditions, will use photographs of the skin folds and other skin-on-skin contact areas (henceforth referred to as "target area[s]") to assess the status of erythema, maceration, denudation, and satellite lesions in the target areas when the SPT is first applied (Day 0), and on Days 1, 3, and 5, during SPT changes. The Principal Investigator (PI) or qualified designee will take photographs of the target areas and assess moisture and odor in these areas. Participants will provide their impressions of pain, itching and burning in the target area(s) on the same days as the skin fold condition photography. In addition, the study will include feedback from the Health Care Providers (HCPs) about the SPT and overall experience of the participants with the SPT.

NCT ID: NCT05704114 Completed - Acne Vulgaris Clinical Trials

Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne

Start date: February 1, 2021
Phase: Phase 4
Study type: Interventional

The purpose of the study is to assess the safety and efficacy of Arazlo Lotion (Tazarotene 0.045% Lotion) for treatment of postinflammatory erythema and postinflammatory hyperpigmentation in subjects with acne.

NCT ID: NCT05622253 Completed - Acne Vulgaris Clinical Trials

Combined Low-Dose Isotretenion and Long-Pulsed 1064 ND-YAG Laser in the Treatment of Acne Erythema

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Acne erythema consists of telangiectasia and erythematous papules, without a comedo, which occurs as a result of inflammatory acne. Moreover, although acne erythema is common in acne patients, no satisfactory medical or surgical treatment is available for this condition. Some acne erythema lesions may improve with time, but the persistent acne erythema, which is experienced by most patients, is cosmetically unacceptable and leads to frustration and psychological distress.

NCT ID: NCT05562661 Completed - Rosacea Clinical Trials

M89PF in Rosacea Associated With Erythema and Sensitive Skin

Start date: January 2, 2021
Phase:
Study type: Observational

Rosacea is a common facial dermatosis, with flares induced by exposome factors. M89PF containing Vichy mineralizing water, probiotic fractions, hyaluronic acid, niacinamide and tocopherol repairs the skin barrier and reinforces skin defences against exposome factors. This study assessed the benefit of M89PF in patients with rosacea associated with erythema and sensitive skin during the Covid-19 pandemic with use of protective face masks.

NCT ID: NCT05476406 Completed - Skin Hydration Clinical Trials

Clinical Study to Evaluate the Impact of aKwa Skincare System on Skin Health

Start date: April 11, 2019
Phase: N/A
Study type: Interventional

The purpose of the study was to evaluate the effectiveness of the äKwä 6-step skincare system by measuring skin moisture level, fine lines and wrinkles, porphyrin count, red spots, and red vasculature counts over a 30-day period.

NCT ID: NCT05360784 Completed - Ocular Redness Clinical Trials

"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"

Start date: May 13, 2022
Phase: Phase 3
Study type: Interventional

This is a multi-center, double-masked, randomized, active-controlled, parallel-group, efficacy and safety study that will enroll 386 participants at up to six clinical sites. Participants with ocular redness will be randomized to receive either brimonidine tartrate ophthalmic solution 0.025%, preservative-free formulation, or Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will be treated with study drug for approximately 4 weeks.

NCT ID: NCT05300542 Completed - Erythema Clinical Trials

Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema

Start date: March 17, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to determine the erythema-reducing efficacy of a test product in two concentrations on a light sunburn induced by a sun simulator compared to an untreated control and a placebo product.

NCT ID: NCT04927325 Completed - Digital Technology Clinical Trials

Erythema at Exit Site & Tablet Camera

Start date: June 30, 2021
Phase: N/A
Study type: Interventional

Background: In critical care medicine central venous catheters play an important role in the source of infections. In the daily routine prior to the diagnosis the suspicion of catheter related infection is discussed in the medical team due to signs of systemic inflammation or exit site infection like erythema, induration or tenderness. However, if an erythema at exit site of a central line can be quantified with a tablet camera, is unknown. Methods: Standardized set of photos will be taken of 10 central lines with a reddened exit site and 10 catheters without an erythema (as a control over time) with a tablet camera and a single-lens reflex camera. The percentage of usable images between tablet and single-lens reflex camera will be analysed. Furthermore, two independent clinical experts from dermatology will grade blinded de-identied images on a scale from 0 to 4 (0 - no erythema, 1- very faint, 2 - faint, 3 - bright, 4 - very bright). Objectives: The primary objective of this feasibility study aims to analyze the reliability of a tablet camera as a device for quantification of erythema around an exit site.